| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 1015.01% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 06/30/2023 | 1015.01% | HC Wainwright & Co. | $5 → $27 | Maintains | Buy |
| 06/22/2023 | 106.48% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 04/18/2023 | 106.48% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
| 11/16/2022 | — | JonesTrading | Downgrades | Buy → Hold | |
| 07/15/2021 | 395.56% | JonesTrading | → $12 | Initiates Coverage On | → Buy |
What is the target price for Inhibikase Therapeutics (IKT)?
The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $27.00 expecting IKT to rise to within 12 months (a possible 1015.01% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inhibikase Therapeutics (IKT)?
The latest analyst rating for Inhibikase Therapeutics (NASDAQ: IKT) was provided by HC Wainwright & Co., and Inhibikase Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Inhibikase Therapeutics (IKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibikase Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibikase Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Inhibikase Therapeutics (IKT) correct?
While ratings are subjective and will change, the latest Inhibikase Therapeutics (IKT) rating was a reiterated with a price target of $0.00 to $27.00. The current price Inhibikase Therapeutics (IKT) is trading at is $2.42, which is within the analyst's predicted range.